KR20240044386A - Lpa 길항제로서의 신규 트리아졸-피리딘 치환된 피롤리디닐 및 테트라히드로-2h-피라닐 아세트산 화합물 - Google Patents

Lpa 길항제로서의 신규 트리아졸-피리딘 치환된 피롤리디닐 및 테트라히드로-2h-피라닐 아세트산 화합물 Download PDF

Info

Publication number
KR20240044386A
KR20240044386A KR1020237041165A KR20237041165A KR20240044386A KR 20240044386 A KR20240044386 A KR 20240044386A KR 1020237041165 A KR1020237041165 A KR 1020237041165A KR 20237041165 A KR20237041165 A KR 20237041165A KR 20240044386 A KR20240044386 A KR 20240044386A
Authority
KR
South Korea
Prior art keywords
alkyl
ring
cycloalkyl
methyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041165A
Other languages
English (en)
Korean (ko)
Inventor
핑 천
전웨이 차이
페이 장
페이화 쑨
훙졘 장
훙?? 장
Original Assignee
비바 스타 바이오사이언시즈 (쑤저우) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비바 스타 바이오사이언시즈 (쑤저우) 컴퍼니 리미티드 filed Critical 비바 스타 바이오사이언시즈 (쑤저우) 컴퍼니 리미티드
Publication of KR20240044386A publication Critical patent/KR20240044386A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237041165A 2021-04-30 2022-04-28 Lpa 길항제로서의 신규 트리아졸-피리딘 치환된 피롤리디닐 및 테트라히드로-2h-피라닐 아세트산 화합물 Pending KR20240044386A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/091510 2021-04-30
CN2021091510 2021-04-30
PCT/US2022/026832 WO2022232459A1 (en) 2021-04-30 2022-04-28 Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists

Publications (1)

Publication Number Publication Date
KR20240044386A true KR20240044386A (ko) 2024-04-04

Family

ID=81748636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041165A Pending KR20240044386A (ko) 2021-04-30 2022-04-28 Lpa 길항제로서의 신규 트리아졸-피리딘 치환된 피롤리디닐 및 테트라히드로-2h-피라닐 아세트산 화합물

Country Status (10)

Country Link
US (1) US20250230140A1 (https=)
EP (1) EP4330249A1 (https=)
JP (1) JP2024517769A (https=)
KR (1) KR20240044386A (https=)
CN (1) CN117751106A (https=)
AU (1) AU2022264579A1 (https=)
CA (1) CA3218258A1 (https=)
IL (1) IL308035A (https=)
MX (1) MX2023012830A (https=)
WO (1) WO2022232459A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109878A1 (zh) * 2021-12-15 2023-06-22 武汉人福创新药物研发中心有限公司 三氮唑类lpar1拮抗剂及其用途
WO2025051267A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 一种lpar1拮抗剂及其用途
WO2025051266A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 杂芳环衍生物的lpar1拮抗剂及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126084A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7208240B2 (ja) * 2017-12-19 2023-01-18 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのシクロヘキシル酸トリアゾールアジン
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
WO2020257135A1 (en) * 2019-06-18 2020-12-24 Bristol-Myers Squibb Company Triazole carboxylic acids as lpa antagonists
WO2022034568A1 (en) * 2020-08-11 2022-02-17 Viva Star Biosciences Limited Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists

Also Published As

Publication number Publication date
WO2022232459A1 (en) 2022-11-03
EP4330249A1 (en) 2024-03-06
CN117751106A (zh) 2024-03-22
CA3218258A1 (en) 2022-11-03
IL308035A (en) 2023-12-01
AU2022264579A1 (en) 2023-12-14
JP2024517769A (ja) 2024-04-23
US20250230140A1 (en) 2025-07-17
MX2023012830A (es) 2024-01-19

Similar Documents

Publication Publication Date Title
CN116669727B (zh) 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物
AU2015284135B2 (en) Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
JP2021107414A (ja) コロニー刺激因子−1受容体(csf−1r)阻害剤
KR20240044386A (ko) Lpa 길항제로서의 신규 트리아졸-피리딘 치환된 피롤리디닐 및 테트라히드로-2h-피라닐 아세트산 화합물
JP2016523925A (ja) Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
US20240109887A1 (en) Novel substituted bicyclic aza-heterocycles as sos1 inhibitors
AU2014234908A1 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors
WO2019169539A1 (en) Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection
JP2024538602A (ja) インターロイキン-1活性の阻害剤としての新規の置換スルホニル尿素化合物
JP7389905B2 (ja) ブルトン型チロシンキナーゼ阻害剤としてのイミダゾールカルボキサミド誘導体
US12338255B2 (en) Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
HK40102702A (zh) 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物
HK40116219A (zh) 新型双环经取代的磺酰脲化合物作为白介素-1活性的抑制剂
HK40100136A (zh) 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物
TW202404583A (zh) 吡啶胺衍生物及其作為鉀通道調節劑之用途

Legal Events

Date Code Title Description
PA0105 International application
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250423

Comment text: Request for Examination of Application